{
    "clinical_study": {
        "@rank": "164621", 
        "arm_group": [
            {
                "arm_group_label": "INCS", 
                "arm_group_type": "Experimental", 
                "description": "Fluticasone propionate 400 microgram daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Allergic rhinitis is a common condition caused by inflammation of nasal mucosa. The study\n      was performed to gain information on this inflammation, including effect of intranasal\n      corticosteroid treatment hereupon and potential influence on the lower airways, ie asthma.\n\n      The study was randomised, placebo-controlled double-blind in patients, monoallergic to\n      grasspollen, presenting symptoms of rhinitis and asthma during season.\n\n      Treatment,ie intranasal corticosteroid or placebo, were given four weeks. After two weeks of\n      treatment intranasal allergen challenge was performed. Measurements were performed during\n      the full study period.\n\n      The study was performed out of pollen season."
        }, 
        "brief_title": "Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge", 
        "completion_date": {
            "#text": "April 1997", 
            "@type": "Actual"
        }, 
        "condition": [
            "Allergic Rhinitis", 
            "Asthma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Inflammation", 
                "Rhinitis", 
                "Bronchial Hyperreactivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  monoallergy to grass\n\n          -  symptoms of allergic rhinitis for at least the two most recent grasspollen seasons\n\n          -  asthma symptoms of asthma for at least two of the four most recent grasspollen\n             seasons\n\n          -  age 18 or older\n\n        Exclusion Criteria:\n\n          -  pregnancy or lactation\n\n          -  fertile women, not sterilised or using sufficient anticonception\n\n          -  Corticosteroid treatment (parenteral, oral, inhaled or intranasal) within two months\n             prior to enrolment\n\n          -  Any other disease, condition or treatment, which to the discretion of the\n             investigator has the potential to interfere with study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657097", 
            "org_study_id": "RHINO97"
        }, 
        "intervention": [
            {
                "arm_group_label": "INCS", 
                "intervention_name": "INCS", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 3, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aarhus", 
                    "country": "Denmark", 
                    "zip": "DK-8000 C"
                }, 
                "name": "Department of Respiratory Diseases, Aarhus University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge. Impact on Bronchial Hyperresponsiveness and the Effect of Intranasal Corticosteroid Treatment", 
        "other_outcome": [
            {
                "measure": "Bronchial metacholine challenge", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Acoustic rhinometry", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Spirometry (Forced Expiratory Volume 1 second (FEV-1))", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Nasal symptom score", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Asthma symptom score", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "overall_official": {
            "affiliation": "Department of Respiratory Diseases, Aarhus University Hospital", 
            "last_name": "Ronald Dahl, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 1997", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Serum Eosinophil Cationic Protein (ECP)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657097"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum Eosinophil Peroxidase (EPO)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Nasal lavage Eosinophil Cationic Protein (ECP)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Nasal lavage Eosinophil Peroxidase (EPO)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Blood Eosinophils", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}